Oregovomab
Based on 1 Customer Validation
Oregovomab (Alt-2 monoclonal antibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells.
For research use only. We do not sell to patients.
- Purity: 99.66%
- CAS No.: 213327-37-8
- Molecular Weight:146.72 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
MUC16
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-kappa
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 213327-37-8
-
Appearance Liquid
-
Molecular Weight 146.72 kDa
-
Color Colorless to light yellow
-
SMILES
[Oregovomab]
-
Synonyms
Alt-2 monoclonal antibody; MAB-B43.13; Oregovamab
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (255 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Pietragalla A, et al. Oregovomab: an investigational agent for the treatment of advanced ovarian cancer. Expert Opin Investig Drugs. 2021 Feb;30(2):103-110. [Content Brief]
[2]. Sparholt MH, et al. Is tissue CA125 expression in epithelial ovarian adenocarcinoma heterogenic? APMIS. 2013 Jan;121(1):38-44. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)